ReviewMolecular microbiology2021
A framework for signaling throughout the life cycle of Babesia species.
Review in Molecular microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Ribosomal architecture and rRNA modification landscape in the tick-borne parasite Babesia divergens.Nature communications · 2026Article
- Recent advancements in phytotherapeutics for controlling babesiosis and theileriosis.Tropical animal health and production · 2026Review
- Ribosomal Architecture and rRNA Modification Landscape in the Tick-Borne ParasitebioRxiv : the preprint server for biology · 2025Article
- Human babesiosis: The past, present and future.Expert reviews in molecular medicine · 2025Review
- Genetic resistance to vector-borne hemoprotozoa in livestock: molecular markers, host-parasite interactions, and implications for breeding and control.Journal of veterinary science · 2025Review
- Identification of a Tick Midgut Protein Involved inMicroorganisms · 2025Article
- Comparative Transcriptome Analysis ofVaccines · 2024Article
- Article
- Nucleic Acid Prevalence of ZoonoticTropical medicine and infectious disease · 2023Review
- Evaluating the inhibitory effect of resveratrol on the multiplication of severalFrontiers in pharmacology · 2023Article
- Comparative single-cell transcriptional atlases of Babesia species reveal conserved and species-specific expression profiles.PLoS biology · 2022Article
- Activity of Apo-Lactoferrin on Pathogenic Protozoa.Pharmaceutics · 2022Review
- Isolation of viable Babesia bovis merozoites to study parasite invasion.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Babesia species are tick-borne intracellular parasites that infect the red blood cells of their mammalian host, leading to severe or fatal disease. Babesia spp. infect a wide range of mammalian species and cause a significant economic burden globally, predominantly through disease in cattle. Several Babesia spp. are increasingly being recognized as zoonotic pathogens of humans. Babesia spp. have complex life cycles involving multiple stages in the tick and the mammalian host. The parasite utilizes complex signaling pathways during replication, egress, and invasion in each of these stages. They must also rapidly respond to their environment when switching between the mammalian and tick stages. This review will focus on the signaling pathways and environmental stimuli that Babesia spp. utilize in the bloodstream and for transmission to the tick, with an emphasis on the role of phosphorylation- and calcium-based signaling during egress and invasion. The expanding availability of in vitro and in vivo culture systems, genomes, transcriptomes, and transgenic systems available for a range of Babesia spp. should encourage further biological and translational studies of these ubiquitous parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.